Boehringer Ingelheim is Committed to Transforming the Lives of People with Cancer 

Summary of Partnership:
At Boehringer Ingelheim, cancer care is personal – today and for generations. We have a clear aspiration to transform the lives of people with cancer by delivering breakthrough therapies.   

Boehringer has partnered with Susan G. Komen to support Komen’s Integrate Patient Insights into Research and Development (InSPIReD) Program. Through this collaboration, Boehringer is committed to supporting people living with cancer and their families by integrating their perspectives and needs into the development of our medicines, design and conduct of our clinical trials, and support services. We ensure that patient and healthcare representatives are involved early on within the process to improve education, disease awareness, and access to healthcare services. 

Boehringer Ingelheim’s generational commitment to driving scientific innovation is reflected by the company’s robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. Boehringer’s ambition in oncology is to take a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

About Boehringer Ingelheim 
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim U.S. – Life Forward.